Meiji Seika to expand in Russian pharmaceutical market

Japanese drugmaker Meiji Seika Pharma has signed a partnership agreement with R-Pharm, one of Russia’s largest pharmaceutical producers, which involves the promotion and sales of two Meiji drugs in Russia, with the possibility of their further production.

Under the terms of the agreement at the initial stage, R-Pharm will focus on the promotion and sales of Meiji products such as the antibiotic cefditoren and hyaluronic acid for articular injections.

According to Vasily Ignatiev, director general of R-pharm, the Russian company will buy Meiji drugs and pay royalties to the Japanese company, and will also provide investments for the promotion and distribution of Meiji drugs in Russia.